Data feasibility in Healthcare: Comparing fit-for-purpose and fit-for-training

Healthcare organizations are investing heavily in both real-world evidence (RWE) studies and artificial intelligence (AI). At first glance, these two fields seem to rely on the same raw material: large healthcare datasets drawn from electronic health records (EHRs), claims databases, registries, genomics, imaging, and patient-generated data. Because the source data often overlaps, it is tempting… Continue reading Data feasibility in Healthcare: Comparing fit-for-purpose and fit-for-training

How EMA Is Redefining Credibility in Real-World Evidence

Why Governance May Become the New Competitive Advantage in RWE   The publication of the European Medicines Agency’s new Data Quality Framework for EU medicine regulation: application to Real-World Data (RWD) marks an important moment in the evolution of Real-World Evidence (RWE) research in Europe. While much of the discussion around RWE has traditionally focused… Continue reading How EMA Is Redefining Credibility in Real-World Evidence

Opt-Out Health Data Governance: Comparing Germany’s and France’s Regulatory Model

The ability to reuse routinely collected healthcare data has become a central aspect of modern clinical research and real-world evidence (RWE) generation. Across Europe, governments are reforming their legal frameworks to enable large-scale health data analysis while maintaining strong protections for patient privacy and individual rights. Two particularly instructive examples are Germany and France.  … Continue reading Opt-Out Health Data Governance: Comparing Germany’s and France’s Regulatory Model

Do We Still Need Country-Specific Data?

In the European Union, data on racial or ethnic origin are classified as a “special category” under Article 9 of the GDPR, which generally prohibits their processing unless specific conditions are met, such as explicit consent or substantial public interest safeguards. As a result, several EU countries, including France, Germany, Denmark, and Sweden, do not… Continue reading Do We Still Need Country-Specific Data?

Operational Challenges of Conducting RWD Studies in China

by Monique Samuels     The use of real-world data (RWD) is growing across the industry and is increasingly encouraged by regulatory agencies worldwide. RWD can provide insights into patient populations, treatment patterns, and outcomes outside of controlled clinical trials. China, with its large and diverse patient population, offers an important opportunity for global evidence… Continue reading Operational Challenges of Conducting RWD Studies in China